All Stories

  1. Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging – Commentary
  2. Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: A case report
  3. “Brain reserve” and “cognitive reserve” should always be taken into account when studying neurodegeneration – NO
  4. Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations
  5. Measurement of Cortical Thickness and Volume of Subcortical Structures in Multiple Sclerosis: Agreement between 2D Spin-Echo and 3D MPRAGE T1-Weighted Images
  6. Comparison between gadolinium-enhanced 2D T1-weighted gradient-echo and spin-echo sequences in the detection of active multiple sclerosis lesions on 3.0T MRI
  7. Multiple sclerosis: Dimethyl fumarate is coming of age
  8. Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper
  9. Grey matter atrophy is associated with disability increase in natalizumab-treated patients
  10. Precision medicine in multiple sclerosis
  11. An uncommon first manifestation of multiple sclerosis: Tako-Tsubo cardiomyopathy
  12. Leptomeningeal enhancement in Susac’s syndrome and multiple sclerosis: Time to expect the unexpected?
  13. Brain Volume Loss During the First Year of Interferon-Beta Treatment in Multiple Sclerosis: Baseline Inflammation and Regional Brain Volume Dynamics
  14. Longitudinal fMRI studies: Exploring brain plasticity and repair in MS
  15. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines
  16. Lesion filling effect in regional brain volume estimations: a study in multiple sclerosis patients with low lesion load
  17. Highlights from the 31st ECTRIMS congress – Barcelona 2015
  18. Should we systematically test patients with clinically isolated syndrome for auto-antibodies?
  19. Onset-adjusted incidence of multiple sclerosis in the Girona province (Spain): Evidence of increasing risk in the south of Europe
  20. Juxtacortical Lesions and Cortical Thinning in Multiple Sclerosis
  21. Predictive value of early brain atrophy on response in patients treated with interferon β
  22. Treating relapsing–remitting multiple sclerosis: therapy effects on brain atrophy
  23. Significant clinical worsening after natalizumab withdrawal: Predictive factors
  24. Brain atrophy in natalizumab-treated patients: A 3-year follow-up
  25. Defining high, medium and low impact prognostic factors for developing multiple sclerosis
  26. Quantifying brain tissue volume in multiple sclerosis with automated lesion segmentation and filling
  27. Adherence in multiple sclerosis (ADAMS): Classification, relevance, and research needs. A meeting report
  28. Evaluating the response to glatiramer acetate in relapsing–remitting multiple sclerosis (RRMS) patients
  29. Diagnosis and trials of clinically isolated syndrome
  30. Predictive markers of disease evolution after a CIS in everyday practice
  31. Multiple sclerosis registries in Europe – results of a systematic survey
  32. One step forward in the quest for evidence of the efficacy of cognitive rehabilitation in multiple sclerosis
  33. Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study
  34. Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment
  35. Clinical impact of early brain atrophy in clinically isolated syndromes
  36. Preliminary validation study of the Spanish version of the satisfaction with life scale in persons with multiple sclerosis
  37. Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes
  38. Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration
  39. Localized grey matter atrophy in multiple sclerosis: A meta-analysis of voxel-based morphometry studies and associations with functional disability
  40. Idiopathic Inflammatory Demyelinating Diseases of the Brainstem
  41. Brain atrophy and lesion load predict long term disability in multiple sclerosis
  42. The International Multiple Sclerosis Clinic – A Virtual Tour of Best Practice Multiple Sclerosis Nursing
  43. Assess, compare and enhance the status of Persons with Multiple Sclerosis (MS) in Europe: a European Register for MS
  44. Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision
  45. Fe de errores de «Anticuerpos monoclonales en desarrollo en esclerosis múltiple»
  46. Value of NMO-IgG determination at the time of presentation as CIS
  47. Increase in the prevalence of multiple sclerosis over a 17-year period in Osona, Catalonia, Spain
  48. Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response
  49. Anticuerpos monoclonales en desarrollo en esclerosis múltiple
  50. Monoclonal antibodies in development in multiple sclerosis
  51. THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis
  52. A functional magnetic resonance proof of concept pilot trial of cognitive rehabilitation in multiple sclerosis
  53. Using the WHOQOL-DIS to Measure Quality of Life in Persons with Physical Disabilities Caused by Neurodegenerative Disorders
  54. Multiple sclerosis: Lesion location may predict disability in multiple sclerosis
  55. A missense HTRA1 mutation expands CARASIL syndrome to the Caucasian population
  56. Brainstem lesions in clinically isolated syndromes
  57. Development and pilot phase of a European MS register
  58. Primary progressive multiple sclerosis diagnostic criteria: a reappraisal
  59. Clinical features of CIS of the brainstem/cerebellum of the kind seen in MS
  60. Plasma levels of 15d-PGJ2are not altered in multiple sclerosis
  61. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis
  62. Measures in the first year of therapy predict the response to interferon β in MS
  63. Brain volumetry counterparts of cognitive impairment in patients with multiple sclerosis
  64. A Single, Early Magnetic Resonance Imaging Study in the Diagnosis of Multiple Sclerosis
  65. Role of MRI criteria and OB for diagnosing multiple sclerosis in patients presenting with clinically isolated syndromes
  66. New treatment measurements for treatment effects on relapses and progression
  67. Mapping the brain pathways of declarative verbal memory: Evidence from white matter lesions in the living human brain
  68. Research Highlights
  69. Very early scans for demonstrating dissemination in time in multiple sclerosis
  70. Predicting progression in primary progressive multiple sclerosis: A 10-year multicenter study
  71. Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis
  72. Magnetisation transfer ratio in the normal appearing white matter predicts progression of disability over 1 year in early primary progressive multiple sclerosis
  73. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?
  74. Normal-Appearing Brain T1 Relaxation Time Predicts Disability in Early Primary Progressive Multiple Sclerosis
  75. Baseline MRI predicts future attacks and disability in clinically isolated syndromes
  76. Variations in chemokine receptor and cytokine expression during pregnancy in multiple sclerosis patients
  77. Regional Gray Matter Atrophy in Early Primary Progressive Multiple Sclerosis
  78. Plasma cerebrosterol and magnetic resonance imaging measures in multiple sclerosis
  79. Metabolite changes in early relapsing–remitting multiple sclerosis
  80. Long-term clinical outcome of primary progressive MS: Predictive value of clinical and MRI data
  81. Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study
  82. Metabolite Changes in Normal-Appearing Gray and White Matter Are Linked With Disability in Early Primary Progressive Multiple Sclerosis
  83. Gray and white matter volume changes in early RRMS: A 2-year longitudinal study
  84. Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis
  85. Decreased MMP-9 production in primary progressive multiple sclerosis patients
  86. Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosis
  87. Specificity of Barkhof Criteria in Predicting Conversion to Multiple Sclerosis When Applied to Clinically Isolated Brainstem Syndromes
  88. APS and the brain
  89. Clinically definite multiple sclerosis after radiological Schilder-like onset
  90. Unconventional therapy in multiple sclerosis
  91. Myelopathy in seronegative Sjögren syndrome and/or primary progressive multiple sclerosis
  92. C onversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, cerebrospinal fl uid and neurophysiological findings
  93. New diagnostic criteria for multiple sclerosis: Application in first demyelinating episode
  94. The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-β
  95. Response to botulinum toxin in a case of rigid spine syndrome
  96. Polyglandular autoimmune syndrome type II and multiple sclerosis
  97. Transient Ischaemic Attack: A Common Initial Manifestation of Cardiac Myxomas
  98. Anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis
  99. Anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis
  100. Lower motor neuron disease in a HIV-2 infected woman
  101. Mitral papillary fibroelastoma as a cause of cardiogenic embolic stroke: report of two cases and review of the literature
  102. Oftalmoplejía bilateral aguda con elevación de anticuerpos anti-GQ1b
  103. Daclizumab to treat multiple sclerosis